Show simple item record

dc.contributor.authorAcıbucu, Fettah
dc.contributor.authorDökmetaş, Hatice Sebila
dc.contributor.authorOğuz Acıbucu, Duygu
dc.contributor.authorKılıçlı, Fatih
dc.contributor.authorAydemir, Mikail
dc.contributor.authorÇakmak, Ecir Ali
dc.date.accessioned10.07.201910:49:13
dc.date.accessioned2019-07-10T19:55:58Z
dc.date.available10.07.201910:49:13
dc.date.available2019-07-10T19:55:58Z
dc.date.issued2017en_US
dc.identifier.citationAcıbucu, F., Dökmetaş, H. S., Oğuz Acıbucu, D., Kılıçlı, F., Aydemir, M. ve Çakmak, E. A. (2017). Effect of vitamin D treatment on serum sclerostin level. Experimental and Clinical Endocrinology & Diabetes, 125(9), 634-637. https://dx.doi.org/10.1055/s-0035-1559790en_US
dc.identifier.issn0947-7349
dc.identifier.issn1439-3646
dc.identifier.urihttps://dx.doi.org/10.1055/s-0035-1559790
dc.identifier.urihttps://hdl.handle.net/20.500.12511/2502
dc.descriptionWOS: 000413852500008en_US
dc.descriptionPubMed ID: 26824280en_US
dc.description.abstractObjective Sclerostin is an osteocyte-secreted endogenous inhibitor of Wnt signaling. Several systemic and local factors have been suggested as possible regulators of sclerostin expression by osteocytes. In this study, we examined the effect of vitamin D treatment on sclerostin levels. Subject and Methods 44 patients with diagnosis of vitamin D deficiency (25(OH)D20ng/ml) were involved in the study. Patients had monthly intramuscular injection of 300.000IU cholecalciferol for 3 consecutive months. Sclerostin, 25(OH)D, parathyroid hormone (PTH), calcium, phosphorus and alkaline phosphatase (ALP) levels were measured during the diagnosis and after the replacement of vitamin D. Results 8 male and 36 female patients were enrolled in the study. Minimum age, maximum age and average age were 21, 55 and 32.02 +/- 9.26 years, respectively. A statistically significant difference was observed between the pre-treatment and post-treatment values in 25(OH)D levels (p:0.001, 10.27 +/- 4.62ng/ml and 51.40 +/- 14.62ng/ml, respectively), PTH levels (p:0.001, 50.32 +/- 19.05pg/ml and 33.97 +/- 13.12pg/ml, respectively) and sclerostin levels (p:0.002, 858.98 +/- 351.63pg/ml and 689.52 +/- 197.92pg/ml, respectively). No statistically significant difference, however, was found between the pre-treatment and post-treatment calcium, phosphorus and ALP levels. Correlation analysis made on pre-treatment and post-treatment sclerostin levels and 25(OH)D, PTH, calcium, phosphorus and ALP levels revealed no statistically significant correlation. Conclusion Our findings show that the sclerostin level of patients with vitamin D deficiency decreases considerably through treatment.en_US
dc.language.isoengen_US
dc.publisherJohann Ambrosius Barth Verlag Medizinverlage Heidelberg GMBHen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectSclerostinen_US
dc.subjectVitamin D Deficiencyen_US
dc.subjectParathyroid Hormoneen_US
dc.titleEffect of vitamin D treatment on serum sclerostin levelen_US
dc.typearticleen_US
dc.relation.journalExperimental and Clinical Endocrinology & Diabetesen_US
dc.departmentİstanbul Medipol Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, İç Hastalıkları Ana Bilim Dalıen_US
dc.identifier.volume125en_US
dc.identifier.issue9en_US
dc.identifier.startpage634en_US
dc.identifier.endpage637en_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.identifier.doi10.1055/s-0035-1559790en_US


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record